Sunday, September 13, 2026

Can AI Speed Up Drug R&D?: PharmGen Science Teams With Polaris AI Pharma Across the Full Development Cycle

PharmGen Science partners with Polaris AI Pharma to enhance drug development using AI technologies and optimize R&D processes.

New Class 4 Disease Regulations on Candida Auris Starting March 29 in South Korea

KDCA classifies Candida auris as a Class 4 infectious disease, enhancing surveillance and management to combat this resistant pathogen.

PIXELL by 4By4 Lands on AWS Marketplace, Goes Global

4By4 lists its image enhancement AI, PIXELL, on AWS Marketplace, expanding global reach for advanced image quality solutions.

Tag: acquisitions

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Samsung Biologics’ Q2 Success: 30% Revenue Growth and Global Expansion Plans

Samsung Biologics exceeded Q2 market expectations due to stable performance from existing plants and new facilities in the U.S.

Eli Lilly vs. Novo Nordisk: A $1.2 Billion Bet Reveals Two Very Different Futures for Obesity Drugs

Eli Lilly and Novo Nordisk are pursuing different strategies in the obesity treatment market, focusing on expansion versus core strengths.

Big Pharma Braces for $300 Billion Loss as Blockbuster Drug Patents Expire

Global pharma faces $300B losses from patent expirations, prompting a shift to multi-indication drugs and innovative therapies.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.